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Abstract
Background: Primary adenoid cystic carcinomas (ACCs) of the trachea are rare tumors of the central bronchial system.
In patients presenting with unresectable tumors, severe comorbidities, or incomplete surgical resection, definitive
radiotherapy is currently the recommended treatment. Irradiation with carbon ions (C12) has shown promising local
control (LC) and survival rates in cases of ACCs of the head and neck. No data on the therapeutic efficacy of C12
radiotherapy in treating tracheal ACC has been published.
Methods: All patients with histologically confirmed ACC of the trachea treated with surgery and/or radiation treatment at
Heidelberg University Hospital between 1991 and 2017 were included in this analysis. Patient and treatment
characteristics, short- and long-term toxicity after radiotherapy, overall survival (OS), freedom from local progression (FFLP),
and freedom from distant progression (FFDP) were prospectively acquired and retrospectively analyzed.
Results: Thirty-eight patients (23 women and 15 men) with a median age of 51 were treated by surgery (n = 20) and/or
radiotherapy with either C12 (n = 7) or photons (n = 24). Of these patients, 61% presented with locally advanced (stage 4)
ACC. The median follow-up for all patients was 74.5months. The 5-year OS for all patients was 95% (10-year: 81%). The 5-
year FFLP and FFDP were 96% (10-year: 83%) and 69% (10-year: 53%), respectively. In patients who underwent surgery
alone, the 5-year OS was 100% (10-year: 80%). The 5-year FFLP and FFDP were 100% (10-year: 100%) and 80% (10-year:
60%), respectively. In patients who underwent radiotherapy alone, the 5-year OS was 100% (10-year: 83%). The 5-year
FFLP and FFDP were 88% (10-year: 44%) and 67% (10-year: 34%), respectively. In patients who received multi-modal
treatment including surgery and adjuvant radiotherapy, the 5-year OS was 84% (10-year: 84%). The 5-year FFLP was 100%
(10-year: 100%) and the 5-year FFDP was 65% (10-year, 65%).
Conclusions: The long-term prognosis is favorable if surgery is performed. In cases of an incomplete resection, good OS
can still be achieved following adjuvant radiotherapy. For radiotherapy, irradiation with C12 shows promising first results.
However, more data is needed to prove the long-term advantage of C12 over photons.
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Background
Two thirds of all tracheal tumors are malignant. Of these,
75% are squamous cell carcinomas (SCCs) and 15% are
adenoid cystic carcinomas (ACCs) [1, 2]. Typically, people
in their fourth to sixth decade of life are affected. An over-
all 5-year survival rate of 52% and an overall 10-year sur-
vival rate of 29% are reported, which is better than the
expected 5- and 10-year survival rates of patients with
non-small cell lung cancer (NSCLC) [3].
ACCs are categorized as a subtype of NSCLC [4].
However, ACCs differ from NSCLC in many aspects.
ACCs grow primarily in the tracheal lumen, have a
slower growth rate, and rarely develop lymph node and
distant metastases (M), even in advanced tumor stages.
Based on these differences, Bhattacharyya proposed a
modified TNM staging system [5] in which tumor size is
the dominating prognostic factor in determining patient
survival. This implies that an advanced tumor growth
does not exclude a curative treatment approach.
The treatment of choice for ACC patients is the
complete surgical resection [6]. In the case of incom-
plete resection (R1, R2), an adjuvant radiotherapy as a
multi-modal treatment approach is recommended.
Radiotherapy as a definitive therapeutic concept is suit-
able for patients presenting with an unresectable tumor
and/or severe comorbidities. The application of photons
is most common for radiotherapy. Recently, hadron ir-
radiation with carbon ions (C12) has been established for
clinical use with promising results, particularly for ACCs
of the head and neck region and skull-based tumors [7–
10]. Compared to photons, C12 offers a favorable dose
distribution with the possibility of dose escalation and
better biological effectiveness [11–13].
Due to the rareness of tracheal ACC, very little data
from other centers have been published. Here, we present
the data of 38 patients with histologically confirmed ACC
of the trachea who were treated by surgery and/or radio-
therapy with either C12 or photons at our center.
Methods
All patients with histologically confirmed ACC of the
trachea treated with surgery and/or radiation treatment
at the Heidelberg University Hospital between 1991 and
2017 were included in this retrospective analysis. The
characteristics of all patients are summarized in Table 1.
Table 1 Patient characteristics
Characteristic Value (%)
Age, y
Median 51
Range 19–80
Sex
Female 23 (61)
Male 15 (39)
Tumor stage (Bhattachyryya 2004)
Stage 1 5 (13)
Stage 2 5 (13)
Stage 3 5 (13)
Stage 4 23 (61)
UICC Characteristics of stage 4 tumors 23
T stage
T1 0 (0)
T2 0 (0)
T3 2 (9)
T4 21 (91)
N stage
N0 16 (70)
N1 4 (17)
No data 3 (13)
M stage
M0 18 (78)
M1 5 (22)
N1 + M1 1 (4)
Treatment
Surgery 7 (18)
Radiation therapy 18 (47)
C12 6 (33)
Photons 12 (67)
Surgery and radiation therapy 13 (34)
C12 1 (8)
Photons 12 (92)
No treatment 1 (3)
Resection status
R0 9 (45)
R1 10 (50)
R2 1 (5)
Abbreviations: C12 carbon ions
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The overall survival (OS), freedom from local progres-
sion (FFLP), and freedom from distant progression
(FFDP) were calculated according to the Kaplan-Meier
method. Postoperative complications and short- and
long-term toxicity after radiation therapy were evaluated
using the 4.0 Common Terminology Criteria for Adverse
Events (CTCAE) classification. The data was analyzed
using IBM SPSS 25 Statistics (IBM, Armonk, NY, USA).
Results
A total of 38 patients with histologically confirmed ACC
of the trachea were included in this study. The data of
23 female and 15 male patients with a median age of 51
(range: 19–80) years at first diagnosis were evaluated.
The TNM staging was provided by Bhattachyryya [5]. It
was further modified by the authors of this article to in-
clude the factors of M and perineural invasion (Pn),
which is characteristic of ACC and is associated with
local tumor recurrence and impaired overall prognosis
[14]. All TNM staging factors are defined in Table 2.
The TNM staging system is summarized in Table 3.
Of the patients, five were initially diagnosed with stage
1 ACC (13%), five with stage 2 ACC (13%), and five with
stage 3 ACC (13%). Most of the patients (n = 23 / 61%)
presented with locally advanced stage 4 ACC. In 21 of
them, the tumor had spread to adjacent organs or struc-
tures (T4, 91%). However, lymph node metastases were
clinically or histologically confirmed in only four
patients (N1, 17%). No lymph node metastases were de-
tected in 16 patients (N0, 70%; NX: n = 3 / 13%). Clinic-
ally or histologically confirmed M were present in five
patients (M1, 22%; M0: n = 18 / 78%). Combined lymph
node and M were diagnosed in one patient (4%). There
was histological evidence of Pn in five patients (Pn1,
22%; Pn0: n = 20 / 87%; PnX: n = 4 / 17%).
Treatment
Surgery was performed in 20 patients (53%). Eleven pa-
tients (55%) were diagnosed with stage 4 ACC (stage 1:
n = 4 / 20%; stage 2: n = 4 / 20%; stage 3: n = 1 / 5%). All
data is summarized in Table 4.
A radical resection (R0) was achieved in nine pa-
tients (45%) (stage 1: n = 3 / 15%; stage 2: n = 1 / 5%;
stage 4: n = 5 / 25%). An R1 situation remained in 10
patients (50%) (stage 1: n = 1 / 5%; stage 2: n = 3 /
15%; stage 3: n = 1 / 5%; stage 4: n = 5 / 25%). A
macroscopic residue of the tumor (R2) had to be left
in situ in one patient (5%; stage 2).
All patients with an incomplete surgical resection (R1,
R2) underwent adjuvant radiotherapy as a multi-modal
treatment approach (C12: n = 1, photons: n = 10). Fur-
thermore, two R0-resected patients (10%) also received
adjuvant radiotherapy because the tumor was close to
the resection margin (C12: n = 0, photons: n = 2). There-
fore, radiotherapy was performed in 13 (65%) of 20 pa-
tients following surgery (C12: n = 1, photons: n = 12).
In contrast, there was an interdisciplinary discussion
about giving 18 patients (47%) definitive radiotherapy. In
this group, 12 patients (67%) were diagnosed with stage
4 ACC (stage 1: n = 0 / 0%; stage 2: n = 2 / 11%; stage 3:
n = 4 / 22%). Six patients underwent irradiation with C12
(33%), whereupon five were found to have stage 4 ACC
(83%). One patient (17%) had undergone surgery for
ACC in 1986 and was then diagnosed with recurrent
stage 2 ACC 34 years following tumor resection. Twelve
patients (67%) received irradiation with photons (stage
2: n = 1 / 8%; stage 3: n = 4 / 33%; stage 4: n = 7 / 59%).
A palliative setting was recommended for one patient
(no treatment, 3%).
Table 2 Definitions of TNM staging factors for primary ACCs of
the trachea
Stages Definitions
T-Stage
T1 Primary tumor confined to trachea; size < 2 cm
T2 Primary tumor confined to trachea; size > 2 cm
T3 Spread outside the trachea but not to adjacent organs or
structures
T4 Spread to adjacent organs or structures
Tx Unkown or cannot be assessed
N-Stage
N0 No evidence of regional nodal disease
N1 Clinical or histological evidence of regional nodal disease
Nx Unknown or cannot be assessed
M-Stage
M0 No evidence of distant metastases
M1 Clinical or histological evidence of distant metastases
Mx Unknown or cannot be assessed
Pn-Stage
Pn0 No histological evidence of perineural invasion
Pn1 Histological evidence of perineural invasion
Pnx Unkown or cannot be assessed
Table 3 TNM staging system for primary ACCs of the trachea
T-Stage N-Stage M-Stage Pn-Stage
Stage 1 1 0 0 0
Stage 2 2 0 0 0
Stage 3 3 0 0 0
Stage 4 4 0 0 0
any T 1 0 0
any T any N 1 0
any T any N 0 1
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In most cases, both variants of radiotherapy included a
primary plan with 3D conformal radiotherapy, IMRT, or
carbon ion beam therapy as well as a boost plan with 3D
conformal radiotherapy, IMRT, brachytherapy, or carbon
ion beam therapy delivered to the planning target vol-
ume (PTV) in fractions from 1.8 to 5 Gy (Gy). Overall,
the median dose for the PTV1 (primary plan) was 50 Gy
(range: 46–63). A median dose of 16 Gy (range: 0–74)
was applied to the PTV2 (boost plan). Therefore, the
overall median total dose was 66 Gy (range: 48–74.4).
For the irradiation with C12 carbon ion boost, the dose
to PTV1 (photons) was 50 Gy in median (range: 50–54)
and the dose to the PTV2 (C12 carbon ion) was 24 Gy in
median (range: 18–24). In the photon only group, the
dose to PTV1 was also 50 Gy in median (range: 46–54),
and the dose to the PTV2 was 16 Gy in median (range:
8–74). Two patients received treatment with 60Gy (RBE)
and 63Gy (RBE) carbon ion beam only, respectively. Two
other patients received, after the primary plan (PTV1)
with 50Gy photons, a brachytherapy boost with an total
dose of 15Gy in 3 fractions. The resulting total dose in the
C12 group was 72Gy in median (range: 60–74.4) and 66
Gy (range: 48–74) in the photon group. LEM 1 were used
as the RBE model for the carbon ion beam therapy plan-
ning. Treatment calculation was performed with an α/β of
2Gy for organs at risk and the planning target volume. All
data are summarized in Table 5.
Survival and local control
The median follow-up time for all patients was 74.5
months. The median follow-up time for patients who
underwent surgery alone was 185months. The median
follow-up time for patients who underwent surgery and ad-
juvant radiotherapy was 123months. In contrast, the me-
dian follow-up times for patients after definitive C12
treatment and photon treatment were 15.5 and 60months,
respectively. The 5-year OS of all patients was 95% (10-
year: 81%). The 5-year FFLP was 96% (10-year: 83%), and
the 5-year FFDP was 69% (10-year: 53%).
In patients who underwent surgery alone, the 5-year
OS was 100% (10-year: 80%). The 5-year FFLP was 100%
(10-year: 100%) and the 5-year FFDP was 80% (10-year:
60%). In patients who underwent radiotherapy alone, the
5-year OS was 100% (10-year: 83%). The 5-year FFLP
and FFDP were 88% (10-year: 44%) and 67% (10-year:
34%), respectively. The longest follow-up period for C12
irradiation alone was 20 months. After this period, no
patient had developed local or distant progression
(FFLP/FFDP: 100%). Compared to photon irradiation
alone, FFLP was also 100% after 21 months (FFDP: 91%).
The longest follow-up period for photon irradiation
alone was 11.3 years. After this period, FFLP was 43%.
FFDP was 38% after 11.3 years.
Table 4 Treatment characteristics
Surgery
alone
Multi-modal treatment Radiotherapy
alone
Surgery +
C12
Surgery +
photons
C12 Photons
Stage
1
2 (29) 0 (0) 2 (17) 0 (0) 0 (0)
Stage
2
1 (14) 0 (0) 3 (25) 1 (17) 1 (8)
Stage
3
0 (0) 0 (0) 1 (8) 0 (0) 4 (33)
Stage
4
4 (57) 1 (100) 6 (50) 5 (83) 7 (59)
Overall 7 (100) 1 (100) 12 (100) 6
(100)
12 (100)
The number of patients is presented for each stage according to the
treatment method. The percentage is shown in brackets
Table 5 Radiation treatment
Carbon ion only (PTV1)
PTV1 (Gy
RBE)
Dpf (Gy
RBE)
PTV2 (Gy
RBE)
Dpf (Gy
RBE)
TD
(Gy)
(n = 2)
60 3 0 0 60 1
63 3 0 0 63 1
Photons (PTV1) with Carbon ion Boost (PTV2)
PTV1 (Gy) Dpf (Gy) PTV2 (Gy
RBE)
Dpf (Gy
RBE)
(n = 5)
50 2 18 3 68 1
54 2 18 3 72 1
50 2 24 3 74 2
50.4 1.8 24 3 74.4 1
Photons (PTV1) with Brachytherapy Boost (PTV2)
PTV1 (Gy) Dpf (Gy) PTV2 (Gy) Dpf (Gy) (n = 2)
50 2 15 5 65 2
Photons only (PTV1 and PTV2)
PTV1 (Gy) Dpf (Gy) PTV2 (Gy) Dpf (Gy) (n =
22)
46 2 10 2 56 1
46 2 14.4 1.8 60.4 1
48 2 – – 48 1
50 2 – – 50 1
50 2 8 2 58 2
50 2 13.8 2.3 63.8 1
50 2 16 2 66 8
50 2 22 2 72 2
50 2 24 2 74 1
50.4 1.8 9 1.8 59.4 3
54 1.8 72 (SIB) 2,4 (SIB) 72 1
Abbreviations: PTV1 planning target volume 1 = primary plan, PTV2 planning
target volume 2 = boost plan, Gy Gray, RBE relative biological effectiveness, Dpf
Dose per fraction, TD total dose, SIB simultaneous integrated boost
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In patients who received multi-modal treatment including
surgery and adjuvant radiotherapy, the 5-year OS was 84%
(10-year: 84%). The 5-year FFLP was 100% (10-year: 100%),
and the 5-year FFDP was 65% (10-year: 65%). One patient
underwent surgery and adjuvant C12 treatment. The follow-
up period was 20months. After this period, the patient had
not developed any FFLP (FFDP). Compared to surgery and
photon irradiation, FFLP was also 100% after 20months
(FFDP: 91%). The longest follow-up period for multi-modal
treatment with photon irradiation was 12.3 years. After this
period, FFLP was 75%. FFDP was 61% after 12.3 years.
All data is summarized in Table 6. All results for
OS in the different treatment groups are summarized
in Fig. 1. The FFLP and the FFDP are shown in Figs.
2 and 3, respectively.
Toxicity
After radiotherapy, acute toxicity was limited to CTCAE
grade 1 in 16 patients (52%). One patient (3%) showed
grade 2 toxicity, and one patient (3%) showed grade 3.
No toxicity data were available for 13 patients (42%).
Dysphagia, erythema, and mucositis were the most com-
monly observed symptoms and were well treatable. After
C12 radiotherapy (n = 7), mainly CTCAE grade 1 toxicity
was detected (5 patients / 72%). In one case (14%), the
food intake was aggravated by severe stomatitis (CTCAE
grade 4). There were no data available for one patient
(14%). After irradiation with photons, 11 cases of
CTCAE grade 1 toxicity (46%) and one case of grade 2
toxicity (4%) were documented (no data available for 12
patients / 50%). One female patient (4%) was diagnosed
with breast cancer 16 years after photon irradiation.
Discussion
Survival and local control
ACCs arise most often in the salivary glands. In cases of
the advanced tumor stage (T4), incomplete resection (R1,
R2), or perineural invasion (Pn1), studies suggest adjuvant
radiotherapy after surgery. In patients presenting with an
unresectable tumor and/or severe comorbidities, definitive
radiation therapy is indicated [15]. After multi-modal
treatment, the 5- and 10-year OS was 94 and 91%, re-
spectively. After definitive radiotherapy, the 5- and 10-
year OS was up to 56 and 43%, respectively [16, 17].
ACC of the trachea is a very rare and slow-growing
cancer that arises from the mixed seromucinous glands
in the trachea. Therefore, only a few retrospective stud-
ies (particularly after radiation treatment) have been
published to date. The published studies showed a good
5-year OS rate (> 70%) [18, 19]. These results are com-
parable with the OS in our study (5-year OS: 95%; 10-
year OS: 81%). A complete R0 resection is considered
the gold standard in treating tracheal ACC. Due to the
infiltrative growth of ACCs into the surrounding tissue,
incomplete resection margins are often observed follow-
ing surgery. According to the literature, positive resec-
tion margins after surgery occur in 8–82% of all cases [6,
19, 20]. In our study, 55% (n = 11) of the operated pa-
tients had a microscopic (R1) or macroscopic residuum
(R2). Although two published studies showed no signifi-
cant difference in the OS of patients following com-
pletely or incompletely resected ACCs, these results
must be discussed critically [1, 18]. Both published stud-
ies are based on a retrospective analysis of a few patients
with ACC. In addition, the rate of adjuvant radiotherapy
was different in these two studies. Adjuvant radiotherapy
was performed in 75% / 100% of patients after incom-
plete resection. Only 33% / 0% of the patients received
postoperative radiotherapy in the group of completely
resected patients [1, 18]. In our study, 100% of the pa-
tients with incomplete resection (R1/2) received adju-
vant radiotherapy and 22% with complete resection (R0)
received adjuvant radiotherapy. Therefore, postoperative
radiation after incomplete resection may be a possible
explanation for the non-significant differences in OS fol-
lowing incomplete resection versus complete resection.
In contrast, published data from the Massachusetts Gen-
eral Hospital in Boston showed survival benefit in pa-
tients with negative resection margins. In total, 91% of
the patients had positive margins (tracheal, radial, or
both), and only 9% had negative margins [19]. Further-
more, radiation treatment was confirmed in only 82% of
the patients, while 17 patients with positive margins
Table 6 Treatment method and survival
Surgery
alone
Multi-modal treatment Radiotherapy
alone
Overall
Surgery
+ C12
Surgery +
photons
C12 Photons
OS 1-
year
100 100 92 100 100 95
5-
year
100 n.a. 92 n.a. 100 95
10-
year
80 n.a. 82 n.a. 83 81
FFLP 1-
year
100 100 100 100 100 100
5-
year
100 n.a. 100 n.a. 86 96
10-
year
100 n.a. 100 n.a. 43 83
FFDP 1-
year
100 100 91 100 91 94
5-
year
80 n.a. 61 n.a. 76 69
10-
year
60 n.a. 61 n.a. 38 53
Abbreviations: FFDP freedom from distant progression, FFLP freedom from local
progression, n.a. not available, OS overall survival
Högerle et al. Radiation Oncology          (2019) 14:117 Page 5 of 9
received no adjuvant radiation treatment. In our study,
we found no significant prognostic factors for survival
and/or LC. The small number of patients, the inhomo-
geneous treatment, and the different follow-up times of
the subgroups could explain this. Other authors have
identified tumor size, tumor location, age, surgery as an
initial treatment, Pn, type of radiation, and radiation
dose as possible prognostic factors for survival and/or
LC [19–21]. Most of the patients in the current study
presented with locally advanced, stage 4 ACC (61%).
Case reports suggest argon plasma coagulation (APC)
and chemotherapy as alternative treatment options [22,
23]. However, APC is only suitable for the palliative
tumor stage, and chemotherapy alone seems to be inef-
fective [24]. Previous studies recommend surgery as the
best treatment of choice [1, 6].
However, in functionally and/or technically inoperable
patients, definitive radiotherapy is a good therapeutic al-
ternative. Some studies have shown significantly worse
outcomes with only 12–17% 5-year survival rates in pa-
tients after definitive radiation treatment compared to
surgery [25]. However, French data from 2018 show no
Fig. 1 Cumulative overall survival (OS) in years
Fig. 2 Freedom from local progression (FFLP) in years
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significant difference between operated and non-
operated patients, with 5-year survival rates of 82 and
86% [21]. In the current study, the 5- and 10-year OS
rates were not significantly different between surgery
followed by adjuvant radiation treatment (5-year: 92%,
10-year: 82%) and definitive radiotherapy (5-year: 100%,
10-year: 83%). Furthermore, the 5-year-FFLP was not
significantly improved in patients who underwent defini-
tive surgery (100%) compared to those who underwent
radiotherapy alone (87%). But again, the results have to
be considered with caution. Due to the retrospective
evaluation of only a few patients and the different
follow-up times of the sub-groups, there may be a bias
in favor of radiotherapy. Furthermore, as patients with
advanced tumor stages and a poor Karnofsky index are
treated with definitive radiation, there is also a possible
survival bias in favor of surgery.
Particularly in patients who present with inoperable
tracheal ACC, dose escalation with C12 is an option to
improve tumor control, OS, and side effects. In addition
to chordomas and chondrosarcomas, ACCs are one of
the tumor entities that may benefit from escalation ther-
apy with protons, neutrons, or C12. Furthermore, pro-
spective studies have shown an advantage of hadrons
over photons for the treatment of ACC originating in
the salivary glands [26]. Data from 58 patients with ACC
of the head and neck showed significantly better LC,
progression-free survival (PFS), and OS at 5 years in the
group with C12 boosts (59.6, 48.4, and 76.5%, respect-
ively) compared to the photon only group (39.9, 27, and
58.7%, respectively) [27]. The median follow-up was 74
months in the C12 group and 63months in the photon
group. Overall, 90% of patients in the C12 group and
94% of those in the photon group had a T4 tumor. All
patients had macroscopic residual tumors at the start of
treatment. There was no significant difference in OS be-
tween patients who had subtotal resection and inoper-
able ACC [27]. Our results confirm the advantage of C12
irradiation compared to photon irradiation with regard
to improved local (FFLP) and distant (FFDP) control.
The physical and biological advantages of carbon ion
beam therapy allow a dose escalation in the tumor (cu-
mulative median dose in the current study: carbon ions:
72 Gy, photons: 66 Gy) without higher doses to the sur-
rounding normal tissue. Therefore, the tumor control
probability (TCP) is higher without increasing the nor-
mal tissue complication probability (NTCP). In addition,
the higher relative biological effectiveness (RBE) yields
to heavier DNA damage [28].
Toxicity
Overall, radiotherapy was well tolerated. The acute toxic-
ities were mainly limited to CTCAE grades 1 and 2 with
favorable outcomes. No ulceration, fistulation, or necrosis
was reported after radiation treatment. Sixteen years after
photon irradiation, one patient (3%) was diagnosed with a
secondary malignant tumor. This might be a long-term
complication after radiotherapy, as the risk for secondary
malignant tumors is known to be increased [29]. However,
breast cancer is the most common tumor in women. The
lifetime risk for breast cancer is much higher compared to
the risk for secondary malignancy after radiation treat-
ment. Therefore, a random occurrence of breast cancer
cannot be excluded. It can be speculated that the inci-
dence of secondary malignancies might be decreased by
using C12 due to the physical advantages with lower
Fig. 3 Freedom from distant progression (FFDP) in years
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integral doses in the normal tissue compared to radiation
treatment with photons.
Limitations
ACCs are very rare tumors of the central bronchial sys-
tem. The present study retrospectively evaluates the
relatively small number of 38 patients presenting with a
primary ACC of the trachea. Due to the heterogeneity of
the group and the different follow-up times of the sub-
groups, the Kaplan–Meier method is susceptible to bias.
Furthermore, comparison between the groups is difficult
(for example, definitive surgery versus definitive radio-
therapy or irradiation with C12 versus irradiation with
photons). As ACCs are characterized by a slow growth
rate, short follow-up times, particularly for the C12
group, may lead to an underestimated progression rate
of the tumor. However, a longer follow-up and a bigger
sample size are needed to minimize potential errors.
Conclusions
Primary ACC of the trachea differs from NSCLC in
many ways. Although most patients are first diagnosed
as being in an advanced tumor stage, the long-term
prognosis is favorable if surgery is performed. In cases of
an incomplete resection, good OS can still be expected if
an adjuvant radiotherapy as part of a multi-modal treat-
ment approach was employed. In patients presenting
with an unresectable tumor and/or severe comorbidities,
definitive radiotherapy is indicated. For radiotherapy, ir-
radiation with C12 shows promising first results with re-
gard to OS and local (FFLP) and distant (FFDP) control
compared to standard irradiation with photons. How-
ever, more data is needed to prove the long-term advan-
tages of C12 over photons.
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